The epicutaneous immunotherapy (EPIT) approach to allergy treatment is an exciting alternative for those allergy sufferers who have tried other treatments and found them wanting. There’s all you need to know about EPIT technology on the dbv-technologies.com/en/ website.
DBV-Technologies is a French-based company that has been working in this field for a number of years. Its major breakthrough has come with the development of the Viaskin® patch and the technology behind it, which is covered in greater detail in http://www.dbv-technologies.com/en/technology/viaskin-technology/. The secret behind the success of the patch lies in its electrostatically charged backing. This enables it to deliver the antigens contained in the patch in powdered form directly to the skin, rather than into the patient’s bloodstream. This avoidance of the traditional method of administering allergens makes the Viaskin® method both safer and less distressing, especially for younger patients. What’s more, the basic patch concept is extremely versatile. It can be applied equally to the treatment and diagnosis of peanut allergy, cows’ milk protein allergy and house dust mite allergy. It is also suitable for use with all age groups.
Comments are closed.